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Background: This study investigated the efficacy and safety of the inhaled corticosteroid (ICS)/
long-acting beta2-agonist (LABA) combination fluticasone furoate (FF)/vilanterol (VI) in Asian
asthma patients.
Methods: A 12-week, double-blind, double-dummy, active-comparator, parallel-group, multi-
center study. 309 Asian asthma patients (12 years, uncontrolled with high-strength ICS or
mid-dose ICS/LABA) were randomized (1:1) and included in the intent-to-treat population;
155 received once-daily FF/VI 200/25 mcg and 154 received twice-daily fluticasone propionate
(FP) 500 mcg. The primary endpoint was change from baseline in daily evening peak expiratory
flow (PEF) averaged over 12 weeks. Secondary endpoints were mean change from baseline in %
rescue-free 24-h periods, daily morning PEF, % symptom-free 24-h periods, and overall Asthma
Quality of Life Questionnaire score. Safety assessments were performed.
Results: For change from baseline in daily evening PEF, the adjusted mean treatment differ-
ence for FF/VI versus FP of 28.5 L/min (95% confidence interval [CI]: 20.1, 36.9) was clinically
and statistically significant (p < 0.001). For change from baseline in % rescue-free 24-h periods,
the adjusted mean treatment difference (1.0%; 95% CI: e7.3, 9.2) was not statistically0 84206187; fax: þ86 10 64200588.
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of companies.significant (p Z 0.821). Statistical significance could not be inferred for the remaining end-
points due to the statistical hierarchy employed. Incidence of on-treatment adverse events
was similar with FF/VI (26%; 3% treatment-related; n Z 1 serious) and FP (27%; 3%
treatment-related; n Z 2 serious); none were fatal. No further safety concerns were identi-
fied.
Conclusions: FF/VI improved evening PEF over 12 weeks versus FP in Asian patients, with a
similar safety profile. The results are generally consistent with a global study comparing the
same treatments.
ª 2014 Published by Elsevier Ltd.Introduction
Background
Asthma is a chronic condition affecting over 300 million
people worldwide, and, although the prevalence of asthma
in Asia is generally low [1], it is increasing [2]. Inhaled
corticosteroids (ICSs) are considered the most effective
anti-inflammatory treatments for all severities of asthma
and their use is recommended by global [2], Chinese [3],
Filipino [4], and Korean guidelines [5]. For patients with
asthma uncontrolled with low-strength ICS alone, an ICS/
long-acting beta2-agonist (LABA) combination is recom-
mended in preference to increasing ICS strength [2e5].
Another factor contributing to poor asthma control is sub-
optimal adherence [6] and it has been demonstrated that
once-daily therapy may help to improve treatment adher-
ence in asthma patients [7e9]. As asthma control across
Asian countries is sub-optimal [10,11], a once-daily ICS/
LABA combination may be a useful treatment option for
Asian asthma patients.
Fluticasone furoate (FF)/vilanterol (VI) is a once-daily
ICS/LABA combination that has 24-h efficacy in asthma
patients [12e15]. In a global study, FF/VI 200/25 mcg once
daily has demonstrated statistically significant improve-
ments in lung function compared with fluticasone propio-
nate (FP) 500 mcg twice daily [12], which is an established
ICS maintenance therapy for asthma [2].
It is known that responses to treatment can vary across
ethnic groups [16,17], including in Asians [17]. The aim of
this study was to evaluate the efficacy and safety of FF/VI
200/25 mcg once daily, administered via the ELLIPTA1 dry
powder inhaler, in adult asthma patients of Asian ancestry
whose asthma was uncontrolled with high-strength ICS or
mid-strength ICS/LABA. FP 500 mcg twice daily was
included as an active control because it was considered an
appropriate treatment for this patient population. Addi-
tionally, the comparison of FF/VI 200/25 mcg once daily
versus FP 500 mcg twice daily has previously been investi-
gated in a global study, allowing indirect comparison of the
findings of this study conducted in Asia with those from thef the GlaxoSmithKline groupglobal study, which was conducted in Germany, Japan,
Poland, Romania, Russia, and the United States [12].Methods
Study design and patients
This was a randomized, double-blind, double-dummy,
active-comparator, parallel-group, multicenter study (GSK
study number: HZA113714; clinicaltrials.gov registration
number: NCT01498653) conducted at 24 centers in 3
countries (12 China, 10 South Korea, 2 the Philippines)
between January 17, 2012 and February 1, 2013. After a 2-
week run-in period, eligible patients were randomized (1:1)
to FF/VI 200/25 mcg once daily, delivered in the evening via
the ELLIPTA dry powder inhaler (equivalent to a delivered
dose of FF/VI 184/22 mcg), or FP 500 mcg twice daily
delivered via the DISKUS inhaler, for 12 weeks. The
randomization schedule was created using a validated
computer system (RandAll [GSK, London, UK]). Randomi-
zation was conducted following a telephone call to the
Registration and Medication Ordering System (RAMOS [GSK,
London, UK]), in accordance with the randomization
schedule. Follow-up contact was performed 1 week after
the last dose of study medication was taken.
To be eligible at screening, male or female outpatients,
aged 12 years or over (18 years or over if required by local
regulations) with a diagnosis of asthma at least 12 weeks
prior to screening had to demonstrate a forced expiratory
volume in one second (FEV1) of 40e90% predicted normal
and reversibility of 12% and 200 mL 10e40 min after 2e4
inhalations of albuterol (salbutamol). Predicted FEV1 values
were based upon National Health and Nutrition Examination
Survey III, using the Asian adjustment [18]. Patients should
have been using ICS or ICS/LABA for at least 12 weeks prior
to screening, and at a stable strength for at least 4 weeks
prior (equivalent to FP 500 mcg twice daily without a LABA,
or FP/salmeterol 250/50mcg twice daily). Patients were
not eligible if they were current smokers or had a smoking
pack history 10 pack-years, had experienced life-
threatening asthma within the last 10 years, had respira-
tory conditions that had not been resolved within 4 weeks
of screening, had an exacerbation requiring treatment with
oral corticosteroids within 12 weeks, if they had a concur-
rent respiratory disease or any other uncontrolled condi-
tion, or if they had evidence of oral candidiasis.
46 J. Lin et al.During the 2-week run-in period, all patients continued
on their current ICS therapy and were required to cease
LABA therapy the day before screening. A change was made
to the protocol allowing some patients who were receiving
ICS/LABA to switch to an equivalent dose of another ICS, if
the same ICS was not available as a standalone formulation
due to hospital prescribing lists. Additionally, patients’
current short-acting beta2-agonist reliever medication was
replaced with albuterol for use as-needed.
After run-in, patients were randomized to treatment if
they demonstrated a morning FEV1 of 40e90% predicted
normal and had recorded either a score 3 on the com-
bined daytime and night-time asthma symptom scale or
albuterol use on at least 4 of the last 7 days of run-in on a
daily-diary card. Patients were excluded if they had clini-
cally significant abnormal laboratory tests or electrocar-
diogram (ECG) data at screening, changes in asthma
medication, or a respiratory tract, sinus or middle-ear
infection during run-in that changed asthma management
or their ability to participate in the study. Treatment
compliance was assessed throughout the study by reviewing
the dose-counter on the patients’ inhaler. Concomitant
medication use is summarized in e-Appendix 1.
Written, informed consent was obtained from each pa-
tient prior to the performance of any study procedures, and
the study was approved by local ethics committees and
conducted in accordance with the Declaration of Helsinki
[19] and Good Clinical Practice guidelines [20].
Outcome measurements
The primary efficacy endpoint was mean change from
baseline in daily evening peak expiratory flow (PEF) aver-
aged over the 12-week treatment period, which was
measured by patients using an electronic diary with inte-
grated peak flow meter (the AM3 device [eRe-
searchTechnology, Hoechberg, Germany]).
The secondary efficacy endpoints were mean change
from baseline in % rescue-free 24-h periods during the 12-
week treatment period, recorded using the electronic
diary; mean change from baseline in daily morning PEF
averaged over the 12-week treatment period; mean change
from baseline in % symptom-free 24-h periods during the
12-week treatment period, recorded using the electronic
diary; and change from baseline in overall Asthma Quality
of Life Questionnaire (AQLQ [þ12]) score at Week 12.
Other selected endpoints included change from baseline
in Asthma Control Test (ACT) score at Week 12, number of
withdrawals due to lack of efficacy during the treatment
period, and change from baseline in morning FEV1 at
Endpoint (patient’s last on-treatment FEV1 measurement).
Morning FEV1 was measured by spirometry during clinic
visits on Days 1, 28, 56, and 84.
Safety evaluations
Safety endpoints included the incidence of adverse events
(AEs; coded using the Medical Dictionary for Regulatory
Activities dictionary) and serious AEs (SAEs). AEs related to
the pharmacology of steroids (including pneumonia,
candidiasis) or LABA (including cardiovascular events,effects on glucose and potassium) were of special interest.
Clinical laboratory assessments (hematology, clinical
chemistry, and liver function) were performed at screening
and Week 12, vital signs (pulse rate, blood pressure) at
every visit from screening to Week 12, and 12-lead ECG
data, including QT interval using Fridericia’s correction
(QTc[F]), was assessed at screening and Week 12.
Statistical analysis
It was planned to screen a total of 600 patients to
randomize sufficient patients to provide 151 evaluable pa-
tients per treatment group; this number would provide 90%
power to detect a treatment difference for FF/VI compared
with FP of 15 L/min in daily evening PEF. Evaluable patients
were defined as those providing evening PEF data for at
least 4 of the 7 days prior to randomization, and at least 4
days after randomization. All patients who were random-
ized and received at least one dose of study treatment
were included in the intent-to-treat (ITT) population; the
per-protocol (PP) population comprised all patients in the
ITT population who did not have any full protocol de-
viations. Patients with partial protocol deviations were
included in the PP population but their data was excluded
from the date of their deviation onwards.
All efficacy endpoints were analyzed for the ITT popu-
lation using an analysis of covariance (ANCOVA) model with
treatment effects due to baseline, region, sex, age, and
treatment group. For the primary endpoint, only evaluable
patients were included and the analysis was repeated on
the PP population. Additionally, the primary endpoint was
analyzed using a repeated-measures model on the ITT
population using weekly evening PEF means from Weeks
1e12, with interaction terms for week-by-treatment and
week-by-baseline.
Data were analyzed using a step-down closed multi-
plicity testing procedure and a statistical hierarchy was
applied to the efficacy endpoints, whereby failure to
achieve significance (p < 0.05) for the previous treatment
comparison of FF/VI 200/25 mcg once daily versus FP
500 mcg twice daily in the hierarchy meant that
significance could not be inferred for any of the
remaining endpoints. The hierarchy was applied to the
efficacy endpoints in the following order: 1) evening PEF,
2) % rescue-free 24-h periods, 3) morning PEF,
4) % symptom-free 24-h periods, 5) AQLQ (þ12) score.
Results
Study population
Of the 313 patients randomized, four were randomized in
error, and 309 were included in the ITT population; 255
patients (83%) completed the study (Fig. 1) and the most
common reason for withdrawal was lack of efficacy
(n Z 38, 12%). The PP population included 240 patients
(77%), which was lower than expected due to an error at
the sites in the Philippines, whereby the majority of pa-
tients received an incorrect ICS strength during the run-in
period (patients on FP/salmeterol 250/50 mcg twice daily
were switched to FP 500 mcg twice daily during run-in,
Figure 1 CONSORT diagram.
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patients were enrolled despite prior treatment with ICS/
LABA at a dose greater than that stipulated in the
protocol.
Patient demographics and screening/baseline charac-
teristics are presented in Table 1. The majority of patients
(89%) were between 18 and 64 years of age and 59% werefemale. The mean % predicted FEV1 improved during the
run-in period, from 63.45% at screening to 67.53% at base-
line. Mean (standard deviation) treatment compliance was
high for patients receiving active treatment, at 95.7% (9.72)
for FF/VI only via ELLIPTA and 95.4% (8.68) for FP only via
DISKUS; however, it should be noted that compliance was
assessed using the dose counter on the inhalers, and that it
Table 1 Patient demographics, screening and baseline characteristics (ITT population).
Demographic FF/VI 200/25 mcg OD
N Z 155
FP 500 mcg BD
N Z 154
Total
N Z 309
Age 46.9 (12.93) 48.8 (13.41) 47.9 (13.19)
Range 13e71 15e79 13e79
Female, n (%) 96 (62) 86 (56) 182 (59)
Duration of asthma, years 12.39 (12.857) 13.44 (13.551) 12.91 (13.196)
Range 0.0e55.7 0.3e55.0 0.0e55.7
Screening characteristics
Pre-bronchodilator FEV1 (L) 1.669 (0.4237) 1.646 (0.5108) 1.658 (0.4685)
Range 0.72e3.10 0.75e3.68 0.72e3.68
Percent predicted FEV1 63.84 (12.936) 63.07 (12.467) 63.45 (12.690)
Range 40.0e90.0 40.0e89.4 40.0e90.0
Post-bronchodilator FEV1 (L) 2.111 (0.5330) 2.072 (0.6282) 2.092 (0.5818)
Range 0.95e3.48 1.05e4.20 0.95e4.20
Percent reversibility FEV1 27.31 (14.570) 26.98 (14.262) 27.14 (14.395)
Range 12.1e102.6 12.1e89.1 12.1e102.6
Baseline characteristics
Pre-bronchodilator FEV1 (L) 1.777 (0.4933) 1.767 (0.5519) 1.772 (0.5225)
Range 0.77e3.22 0.75e3.41 0.75e3.41
Percent predicted FEV1 67.51 (13.249) 67.55 (13.432) 67.53 (13.319)
Range 40.5e90.0 40.2e89.7 40.2e90.0
All data are presented as mean (SD) unless otherwise stated. BD Z twice daily; FEV1 Z forced expiratory volume in one second;
FF Z fluticasone furoate; FP Z fluticasone propionate; ITT Z intent-to-treat; OD Z once daily; SD Z standard deviation;
VI Z vilanterol.
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inhaling a dose of the study medication.Efficacy
There were improvements from baseline in evening
PEF with both FF/VI (39.1 L/min; standard error [SE]:
3.01) and FP (10.5 L/min; SE: 3.03) (Table 2, Fig. 2). The
adjusted treatment difference for FF/VI compared with FP
(28.5 L/min; 95% CI: 20.1, 36.9) was statistically significant
(p < 0.001) (Table 2, Fig. 3). The adjusted treatment
difference in the PP population for FF/VI versus FP wasTable 2 Statistical analysis of change from baseline in
evening PEF (L/min), Weeks 1e12 (ITT population).
FF/VI 200/25 mcg OD
N Z 155
FP 500 mcg BD
N Z 154
n 154 152
LS mean 302.5 274.0
LS mean
change (SE)
39.1 (3.01) 10.5 (3.03)
FF/VI 200/25 OD versus FP 500 BD
Difference
(95% CI)
28.5 (20.1, 36.9)
p value <0.001
BD Z twice daily; CI Z confidence interval; FP Z fluticasone
propionate; ITT Z intent-to-treat; FF Z fluticasone furoate;
LSZ least-squares; PEFZ peak expiratory flow; SEZ standard
error; VI Z vilanterol; OD Z once daily.28.7 L/min (95% CI: 19.3, 38.2) (Fig. 3) and was also sta-
tistically significant (p < 0.001).
Change from baseline and adjusted treatment differ-
ences for the secondary endpoints are presented in Table 3
and Fig. 3. The comparison of % rescue-free 24-h periods for
FF/VI compared with FP (adjusted treatment difference:
1.0%; 95% CI: e7.3, 9.2) was not statistically significant
(pZ 0.821), but there were numerical improvements from
baseline with both treatments (mean change from baseline:
32.4% with FF/VI; 31.5% with FP). Due to the failure to
achieve statistical significance for this endpoint, and
because of the statistical hierarchy, no inference ofFigure 2 Repeated measures analysis of change from base-
line in evening PEF (L/min) (ITT population).
Figure 3 Adjusted treatment differences for all efficacy endpoints (ITT population).
Fluticasone furoate/vilanterol 200/25 mcg in Asians 49significance could be made for the remaining endpoints and
the following results should be interpreted as descriptive
only. For all of the remaining secondary endpoints,
there were numerical improvements from baseline with
both FF/VI and FP and the adjusted treatment differences
favored FF/VI (morning PEF: 32.3 L/min [95% CI; 23.6,
40.9], % symptom-free 24h periods: 4.9% [e2.8, 12.5], and
overall AQLQ [þ12] score: 0.12 [e0.08, 0.32]).
At Week 12, there were improvements from baseline in
ACT score with both treatments (mean change (SE): 4.7
(0.29) with FF/VI; 4.3 (0.31) for FP) (Fig. 3); 91 (65%) pa-
tients with FF/VI had an ACT score 20, compared with 73
(59%) patients with FP. There was also a lower percentage
of withdrawals due to lack of efficacy in the FF/VI group
(8%) than in the FP group (17%) (Fig. 4). There were nu-
merical improvements from baseline in 12-h post-dose
morning FEV1 at Endpoint with both FF/VI and FP; the
adjusted treatment difference was 0.108L (95% CI: 0.040,
0.176) (Fig. 3).Safety results
A summary of on-treatment AEs, most frequently reported
AEs, and AEs of special interest known to be associated with
either ICS or LABA treatment are presented in Table 4. A
similar proportion of patients reported on-treatment AEswith FF/VI (26%) and with FP (27%). The most frequently
reported on-treatment AE was upper respiratory tract
infection, which was reported by a lower proportion of pa-
tients with FF/VI (n Z 13, 8%) compared with FP (n Z 18,
12%). The incidence of treatment-related AEs was low for
both FF/VI (n Z 5, 3%: n Z 1 oropharyngeal pain and
headache, n Z 2 oropharyngeal pain, n Z 1 oral pares-
thesia, n Z 1 allergic dermatitis) and FP (n Z 5, 3%: n Z 1
oropharyngeal pain, nZ 1 oropharyngeal discomfort, nZ 1
asthma exacerbation, n Z 2 upper respiratory tract infec-
tion). A total of 4 patients (FF/VI: n Z 1 asthma exacerba-
tion, nZ 1 thyroid cancer; FP: nZ 1 asthma exacerbation,
cardiac failure, and respiratory failure, nZ 1 drug eruption)
withdrew from the study due to AEs. There were three on-
treatment SAEs (FF/VI: n Z 1, acute bronchial asthma; FP:
nZ 1 drug rash, nZ 1 asthma exacerbation, cardiac failure,
and respiratory failure); all led to withdrawal from the study
but only the asthma exacerbation with FP was considered to
be treatment-related. There were no deaths during the
study.
Four patients (FF/VI: n Z 1, FP: n Z 3) experienced
severe asthma exacerbations while on treatment and all
were withdrawn from the study as a result. Severe exac-
erbations were only reported as an AE if they met SAE
criteria: three of these exacerbations were not considered
to meet the SAE criteria and were not reported as AEs. More
patients in the FF/VI group (n Z 15, 10%) reported AEs of
Table 3 Statistical analysis of change from baseline for secondary endpoints (ITT population).
FF/VI 200/25 mcg OD
N Z 155
FP 500 mcg BD
N Z 154
Percentage of rescue-free 24h periods, Weeks 1e12
n 155 152
LS mean change (SE) 32.4 (2.95) 31.5 (2.98)
FF/VI 200/25 OD versus FP 500 BD
Difference (95% CI) 1.0 (7.3, 9.2)
p value 0.821
Equivalent number of additional rescue-free days per week
LS mean change from baseline 2.3 2.2
LS mean difference from FP 500 BD 0.1
Morning PEF (L/min), Weeks 1e12
n 154 152
LS mean 307.8 275.5
LS mean change (SE) 46.2 (3.07) 14.0 (3.10)
FF/VI 200/25 OD versus FP 500 BD
Difference (95% CI) 32.3 (23.6, 40.9)
Percentage of symptom-free 24h periods, Weeks 1e12
n 155 152
LS mean change (SE) 25.4 (2.74) 20.6 (2.77)
FF/VI 200/25 OD versus FP 500 BD
Difference (95% CI) 4.9 (2.8, 12.5)
Equivalent number of additional rescue-free days per week
LS mean change from baseline 1.8 1.4
LS mean difference from FP 500 BD 0.3
Overall AQLQ (D12) score, Week 12
n 140 123
LS mean 5.34 5.23
LS mean change (SE) 0.80 (0.069) 0.69 (0.074)
FF/VI 200/25 OD versus FP 500 BD
Difference (95% CI) 0.12 (0.08, 0.32)
AQLQZ Asthma Quality of Life Questionnaire; BDZ twice daily; CIZ confidence interval; FFZ fluticasone furoate; FPZ fluticasone
propionate; ITT Z intent-to-treat; LS Z least-squares; OD Z once daily; PEF Z peak expiratory flow; SE Z standard error;
VI Z vilanterol.
50 J. Lin et al.special interest than in the FP group (n Z 8, 5%); four of
these AEs were considered to be treatment-related by the
investigator (FF/VI: n Z 2 oropharyngeal pain, n Z 1
allergic dermatitis; FP: n Z 1 oropharyngeal pain) and two
were SAEs (cardiac failure, drug eruption, both with FP).
Additionally, pneumonia was reported by two patients inFigure 4 Withdrawals due to lack of efficacy over the
treatment period (ITT population).the FF/VI group; both events were non-serious (1 mild in
intensity; 1 moderate in intensity) and unrelated to study
treatment, and they resolved within 13 days.
There was no evidence of any trend for patients to have
abnormal results for clinical chemistry, liver function, or
hematology assessments. No statistically significant differ-
ences were observed between the two treatment groups
post-baseline for any of the vital signs assessments or for
ECG parameters (including QTc[F]) at Week 12; no patients
were reported as having abnormal clinically-significant ECG
results at screening or at Week 12.Discussion
The aim of this study was to evaluate the efficacy and
safety of FF/VI 200/25 mcg once daily in adult asthma pa-
tients of Asian ancestry. FF/VI 200/25 mcg once daily in the
evening produced a statistically significant and clinically
relevant improvement in evening PEF compared with
FP 500 mcg twice daily. Numerical improvements from
baseline in the percentage of rescue-free 24-h periods were
observed for the treatment comparison of FF/VI versus FP,
however, the adjusted treatment difference was not
Table 4 Overview of AEs, most-frequent AEs (3% in
either treatment arm), and AEs of special interest (ITT
population).
FF/VI 200/25 mcg OD
N Z 155
FP 500 mcg BD
N Z 154
On-treatment AEs
Any AE 40 (26) 41 (27)
Treatment-related AEs 5 (3) 5 (3)
AEs leading to
permanent
discontinuation
of the study drug
2 (1) 2 (1)
Serious AEs 1 (<1) 2 (1)
Treatment-related,
serious AEs
0 1 (<1)
Fatal AEs 0 0
Most-frequent on-treatment AEs (‡3% in either
treatment arm)
Upper respiratory
tract infection
13 (8) 18 (12)
Nasopharyngitis 6 (4) 6 (4)
Rhinitis allergic 5 (3) 2 (1)
Oropharyngeal pain 4 (3) 1 (<1)
AEs of special interest
Patients with any
AE of special
interest
15 (10) 8 (5)
Hypersensitivity 3 (2) 4 (3)
Local steroid effects 4 (3) 1 (<1)
Cardiovascular effects 3 (2) 1 (<1)
Effects on glucose 1 (<1) 2 (1)
Lower respiratory
tract infection,
excluding
pneumonia
2 (1) 0
Pneumonia 2 (1) 0
Data are n (%). AE Z adverse event; BD Z twice daily;
FF Z fluticasone furoate; FP Z fluticasone propionate;
ITT Z intent-to-treat; OD Z once daily; VI Z vilanterol.
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provements from baseline with FF/VI compared with FP for
the remaining secondary and other endpoints. The safety
profiles of FF/VI and FP were generally similar, the overall
incidence of SAEs was low (1% in either treatment group),
and there were no deaths.
In this study, improvements from baseline in lung func-
tion were observed with both FF/VI and FP. The statistically
significant improvement in evening PEF for FF/VI versus FP
in this 12-week study (28.5 L/min [95% CI: 20.1, 36.9]) was
greater than the minimal patient perceivable improvement
of 18.79 L/min [21], and is similar to the improvement
observed at 12 weeks in the previous 24-week global study
[12] of 24.0 L/min (95% CI: 16.3, 31.7) [22]. The use of
evening PEF as a primary endpoint in the present study
provides evidence that in Asian patients, treatment with
FF/VI 200/25 mcg over 12 weeks can significantly improve
lung function 24-h after dosing. The observed numerical
improvements in the adjusted mean treatment differencefor FF/VI 200/25 mcg versus FP 500 mcg in morning PEF
were similar between the present study (32.3 L/min; 95%
CI: 23.6, 40.9]) and the global study (31.0 L/min; 95% CI:
23.3, 38.8) [22], although statistical significance could not
be inferred for this observation in either study. Lung
function is at its lowest in the early morning due to diurnal
variation [23] and, although the endpoints discussed above
measure improvements in trough values (i.e., 24 h post-
dose), the numerical improvements of 108 mL (95% CI: 40,
176) observed in morning FEV1 are also encouraging.
Despite the improvements in lung function for the
comparison for FF/VI 200/25 mcg versus FP 500 mcg, no
statistically significant treatment difference was observed
for rescue-free 24-h periods, which was the first secondary
endpoint in the statistical hierarchy. As a result, statistical
significance for the comparison of FF/VI versus FP for the
remaining endpoints could not be inferred although there
were numerical improvements with FF/VI compared with
FP for all remaining endpoints. The numerical improvement
in the % of rescue-free 24-h periods was slightly less than
that observed over Weeks 1e24 in the global study, and the
difference in % symptom-free 24-h periods was similar to
the improvements over Weeks 1e24 in the global study;
these endpoints were only analyzed as change from base-
line over the 24 week treatment period in the global study
[12]. The numerical improvements from baseline in overall
AQLQ (þ12) score were greater than the minimally impor-
tant difference of 0.5 [24] in both treatment groups (FF/VI:
0.80; FP: 0.69), which was also true at Week 12 in the global
study (FF/VI: 0.74; FP: 0.74) [22]. Patients in both groups
also showed improvements in ACT score by more than the
minimally important difference of 3 [25] (LS mean change
4.7 for FF/VI and 4.3 for FP), which is also consistent with
the global study [12] (LS mean change 4.8 for FF/VI and 3.9
for FP) [22]. Overall, these results indicate that both FF/VI
and FP are effective in establishing control of asthma
symptoms, and although there were numerical improve-
ments with FF/VI compared with FP for symptomatic end-
points, there was no statistically significant difference.
The rates of AEs were similar with both FF/VI (26%) and
FP (27%), the incidence of SAEs was low, and no patients
died during the study. Additionally, the incidence of local
steroid effects was low (only oropharyngeal pain was re-
ported) and the incidence of any LABA-related effects,
including cardiovascular events and glucose effects (no
potassium effects were reported), was low, with events
occurring in 2% of patients in either treatment group. The
incidence of severe asthma exacerbations was low in this
population that was treated with high-strength ICS or mid-
strength ICS/LABA at the time of screening; however, the
interpretation of exacerbation rate is limited by the fact
this 12-week study was not of sufficient length to assess
exacerbation rates over time. Additionally, the strict with-
drawal criteria meant that patients were withdrawn from
the study before they experienced an exacerbation, which
is highlighted by the findings that only four patients expe-
rienced severe asthma exacerbations while on-treatment,
whereas 38 patients were withdrawn due to lack of efficacy.
There were no safety concerns related to clinical laboratory
assessments, vital signs, or ECG parameters in this study and
the safety results are consistent with previous observations
of the 200/25 mcg strength of FF/VI [12,26].
52 J. Lin et al.The patients recruited to this study were treated with
high-strength ICS or mid-strength ICS/LABA at screening,
and represented a suitable patient population in terms of
disease severity for evaluation of the 200/25 mcg strength
of FF/VI. The loss of patients from the PP population in the
Philippines due to the run-in error could be seen as a
weakness; however, the similar results observed for the
primary endpoint between the PP population, which
excluded these patients, and the ITT population, supports
the robustness of the results. This study was limited by the
lack of a placebo arm to which the treatment effects of FF/
VI and FP could be compared, but it is considered unethical
for asthma patients who require high-strength ICS or mid-
strength ICS/LABA maintenance therapy to receive pla-
cebo; moreover FP 500 mcg twice daily was used as a
comparator in this study, and is a high-dose ICS treatment
known to be effective in asthma [2]. The treatment dura-
tion of 12 weeks was considered sufficient to demonstrate
efficacy and tolerability in this study population.
In conclusion, FF/VI 200/25 mcg once daily demon-
strated clinically and statistically significant improvements
in evening PEF compared with FP 500 mcg twice daily in this
study of patients of Asian ancestry aged 12 years and older
with persistent asthma uncontrolled on high-strength ICS or
mid-dose ICS/LABA combination products. Overall, FF/VI
200/25 mcg once daily had an AE profile generally similar to
that of FP 500 mcg twice daily. The results are generally
consistent to the comparison of FF/VI 200/25 mcg once
daily with FP 500 mcg twice daily in the previous global
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